HUMAN ANGIOMOTIN-LIKE PROTEIN 1
The invention provides isolated nucleic acids that encode human angiomotin-like protein (AMPL1), including two isoforms, and fragments thereof, vectors for propagating and expressing AMLP1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SHANNON, MARK PHAN, THUYMY |
| description | The invention provides isolated nucleic acids that encode human angiomotin-like protein (AMPL1), including two isoforms, and fragments thereof, vectors for propagating and expressing AMLP1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel AMLP1 isoforms, and antibodies thereto. The innvention further provides transgenic cells and non-human organisms comprising AMLP2 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the AMLP1 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the AMLP1 nucleic acids, proteins, and antibodies of the present invention.
L'invention concerne des acides nucléiques isolés codant la protéine 1 de type angiomotine humaine (AMLP1), ainsi que deux isoformes et des fragments de ceux-ci, des vecteurs destinés à propager et à exprimer les acides nucléiques d'AMLP1, des cellules hôtes contenant les acides nucléiques et vecteurs selon l'invention, des protéines, des fragments de protéines et des protéines de fusion des nouveaux isoformes d'AMLP1, ainsi que des anticorps. L'invention concerne également des cellules transgéniques et des organismes non humains contenant les acides nucléiques d'AMLP1, ainsi que des cellules transgéniques et des organismes non humains à disruption ciblée de l'orthologue endogène du gène AMLP1. L'invention concerne encore des préparations pharmaceutiques contenant lesdits acides nucléiques, protéines et anticorps. L'invention concerne enfin des méthodes de diagnostic, de recherche et de traitement à base d'acides nucléiques, de protéines et d'anticorps d'AMLP1 selon l'invention. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO03037931A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO03037931A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO03037931A33</originalsourceid><addsrcrecordid>eNrjZJD3CPV19FNw9HP39Pf1D_H00_Xx9HZVCAjyD3H19FMw5GFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8eH-BsYGxuaWxoaOxsbEqAEAzC8hnA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HUMAN ANGIOMOTIN-LIKE PROTEIN 1</title><source>esp@cenet</source><creator>SHANNON, MARK ; PHAN, THUYMY</creator><creatorcontrib>SHANNON, MARK ; PHAN, THUYMY</creatorcontrib><description>The invention provides isolated nucleic acids that encode human angiomotin-like protein (AMPL1), including two isoforms, and fragments thereof, vectors for propagating and expressing AMLP1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel AMLP1 isoforms, and antibodies thereto. The innvention further provides transgenic cells and non-human organisms comprising AMLP2 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the AMLP1 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the AMLP1 nucleic acids, proteins, and antibodies of the present invention.
L'invention concerne des acides nucléiques isolés codant la protéine 1 de type angiomotine humaine (AMLP1), ainsi que deux isoformes et des fragments de ceux-ci, des vecteurs destinés à propager et à exprimer les acides nucléiques d'AMLP1, des cellules hôtes contenant les acides nucléiques et vecteurs selon l'invention, des protéines, des fragments de protéines et des protéines de fusion des nouveaux isoformes d'AMLP1, ainsi que des anticorps. L'invention concerne également des cellules transgéniques et des organismes non humains contenant les acides nucléiques d'AMLP1, ainsi que des cellules transgéniques et des organismes non humains à disruption ciblée de l'orthologue endogène du gène AMLP1. L'invention concerne encore des préparations pharmaceutiques contenant lesdits acides nucléiques, protéines et anticorps. L'invention concerne enfin des méthodes de diagnostic, de recherche et de traitement à base d'acides nucléiques, de protéines et d'anticorps d'AMLP1 selon l'invention.</description><edition>7</edition><language>eng ; fre</language><subject>AGRICULTURE ; ANIMAL HUSBANDRY ; CARE OF BIRDS, FISHES, INSECTS ; CHEMISTRY ; FISHING ; FORESTRY ; HUMAN NECESSITIES ; HUNTING ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; NEW BREEDS OF ANIMALS ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR ; TRAPPING</subject><creationdate>2003</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20031120&DB=EPODOC&CC=WO&NR=03037931A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20031120&DB=EPODOC&CC=WO&NR=03037931A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHANNON, MARK</creatorcontrib><creatorcontrib>PHAN, THUYMY</creatorcontrib><title>HUMAN ANGIOMOTIN-LIKE PROTEIN 1</title><description>The invention provides isolated nucleic acids that encode human angiomotin-like protein (AMPL1), including two isoforms, and fragments thereof, vectors for propagating and expressing AMLP1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel AMLP1 isoforms, and antibodies thereto. The innvention further provides transgenic cells and non-human organisms comprising AMLP2 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the AMLP1 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the AMLP1 nucleic acids, proteins, and antibodies of the present invention.
L'invention concerne des acides nucléiques isolés codant la protéine 1 de type angiomotine humaine (AMLP1), ainsi que deux isoformes et des fragments de ceux-ci, des vecteurs destinés à propager et à exprimer les acides nucléiques d'AMLP1, des cellules hôtes contenant les acides nucléiques et vecteurs selon l'invention, des protéines, des fragments de protéines et des protéines de fusion des nouveaux isoformes d'AMLP1, ainsi que des anticorps. L'invention concerne également des cellules transgéniques et des organismes non humains contenant les acides nucléiques d'AMLP1, ainsi que des cellules transgéniques et des organismes non humains à disruption ciblée de l'orthologue endogène du gène AMLP1. L'invention concerne encore des préparations pharmaceutiques contenant lesdits acides nucléiques, protéines et anticorps. L'invention concerne enfin des méthodes de diagnostic, de recherche et de traitement à base d'acides nucléiques, de protéines et d'anticorps d'AMLP1 selon l'invention.</description><subject>AGRICULTURE</subject><subject>ANIMAL HUSBANDRY</subject><subject>CARE OF BIRDS, FISHES, INSECTS</subject><subject>CHEMISTRY</subject><subject>FISHING</subject><subject>FORESTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HUNTING</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>NEW BREEDS OF ANIMALS</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR</subject><subject>TRAPPING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2003</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJD3CPV19FNw9HP39Pf1D_H00_Xx9HZVCAjyD3H19FMw5GFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8eH-BsYGxuaWxoaOxsbEqAEAzC8hnA</recordid><startdate>20031120</startdate><enddate>20031120</enddate><creator>SHANNON, MARK</creator><creator>PHAN, THUYMY</creator><scope>EVB</scope></search><sort><creationdate>20031120</creationdate><title>HUMAN ANGIOMOTIN-LIKE PROTEIN 1</title><author>SHANNON, MARK ; PHAN, THUYMY</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO03037931A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2003</creationdate><topic>AGRICULTURE</topic><topic>ANIMAL HUSBANDRY</topic><topic>CARE OF BIRDS, FISHES, INSECTS</topic><topic>CHEMISTRY</topic><topic>FISHING</topic><topic>FORESTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HUNTING</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>NEW BREEDS OF ANIMALS</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR</topic><topic>TRAPPING</topic><toplevel>online_resources</toplevel><creatorcontrib>SHANNON, MARK</creatorcontrib><creatorcontrib>PHAN, THUYMY</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHANNON, MARK</au><au>PHAN, THUYMY</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HUMAN ANGIOMOTIN-LIKE PROTEIN 1</title><date>2003-11-20</date><risdate>2003</risdate><abstract>The invention provides isolated nucleic acids that encode human angiomotin-like protein (AMPL1), including two isoforms, and fragments thereof, vectors for propagating and expressing AMLP1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel AMLP1 isoforms, and antibodies thereto. The innvention further provides transgenic cells and non-human organisms comprising AMLP2 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the AMLP1 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the AMLP1 nucleic acids, proteins, and antibodies of the present invention.
L'invention concerne des acides nucléiques isolés codant la protéine 1 de type angiomotine humaine (AMLP1), ainsi que deux isoformes et des fragments de ceux-ci, des vecteurs destinés à propager et à exprimer les acides nucléiques d'AMLP1, des cellules hôtes contenant les acides nucléiques et vecteurs selon l'invention, des protéines, des fragments de protéines et des protéines de fusion des nouveaux isoformes d'AMLP1, ainsi que des anticorps. L'invention concerne également des cellules transgéniques et des organismes non humains contenant les acides nucléiques d'AMLP1, ainsi que des cellules transgéniques et des organismes non humains à disruption ciblée de l'orthologue endogène du gène AMLP1. L'invention concerne encore des préparations pharmaceutiques contenant lesdits acides nucléiques, protéines et anticorps. L'invention concerne enfin des méthodes de diagnostic, de recherche et de traitement à base d'acides nucléiques, de protéines et d'anticorps d'AMLP1 selon l'invention.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO03037931A3 |
| source | esp@cenet |
| subjects | AGRICULTURE ANIMAL HUSBANDRY CARE OF BIRDS, FISHES, INSECTS CHEMISTRY FISHING FORESTRY HUMAN NECESSITIES HUNTING HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY NEW BREEDS OF ANIMALS ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR TRAPPING |
| title | HUMAN ANGIOMOTIN-LIKE PROTEIN 1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T12%3A38%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHANNON,%20MARK&rft.date=2003-11-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO03037931A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |